United States Post-Marketing Observational Cardiovascular Safety Study in Patients taking Naloxegol (Naloxegol US Post-Market Requirement CV Safety)First published 16/03/2017 Last updated 14/03/2024 EU PAS number: EUPAS18201StudyOngoing
EvideraUnited Kingdom First published: 20/11/2013Last updated 07/03/2024 InstitutionLaboratory/Research/Testing facilityNon-Pharmaceutical companyENCePP partner